Evidence map›Paper›PMID 34368780›Full record

ArticleNature cancer2020

PAK4 inhibition improves PD-1 blockade immunotherapy.

Gabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, Jesse M Zaretsky, Theodore S Nowicki, Jennifer Tsoi, Cristina Puig-Saus, Ignacio Baselga-Carretero, Egmidio Medina, Michael J Quist and 11 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 156 citations in OpenAlex.

  1. Trial
  2. Article
  3. Crosstalk Between CTSBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Computational Identification of New Dual PAK4 and NAMPT Inhibitors.International journal of molecular sciences · 2026
    Article
  5. Article
  6. Special Issue "Novel Targeted Therapies and Drugs in Cancer".International journal of molecular sciences · 2026
    Article
  7. Review
  8. Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Globulol fromFrontiers in pharmacology · 2026
    Article
  18. Review
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Gabriel Abril-RodriguezDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Davis Y TorrejonDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Wei LiuLaboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.
Jesse M ZaretskyDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Theodore S NowickiDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA.
Jennifer TsoiDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Cristina Puig-SausDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Ignacio Baselga-CarreteroDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Egmidio MedinaDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Michael J QuistDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Alejandro J GarciaDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
William SenapedisKaryopharm Therapeutics, Newton, MA, USA.
Erkan BalogluKaryopharm Therapeutics, Newton, MA, USA.
Anusha KalbasiDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8692-1457
Gardenia Cheung-LauDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Beata Berent-MaozDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Begoña Comin-AnduixDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Siwen Hu-LieskovanDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Cun-Yu WangLaboratory of Molecular Signaling, Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.
Catherine S Grasso *Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Antoni Ribas *Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458
University of California, Los Angeles · USKaryopharm Therapeutics (United States) · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
Molecular and Genetic Determinants of Invasion in HNSCCR01DE015964 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, CUN-YU · 2004 to 2019
$6.6M
NCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NIAID NIH HHS P30 AI028697NICHD NIH HHS K12 HD000850NIDCR NIH HHS R01 DE015964NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

Lack of tumor infiltration by immune cells is the main mechanism of primary resistance to programmed cell death protein 1 (PD-1) blockade therapies for cancer. It has been postulated that cancer cell-intrinsic mechanisms may actively exclude T cells from tumors, suggesting that the finding of actionable molecules that could be inhibited to increase T cell infiltration may synergize with checkpoint inhibitor immunotherapy. Here, we show that p21-activated kinase 4 (PAK4) is enriched in non-responding tumor biopsies with low T cell and dendritic cell infiltration. In mouse models, genetic deletion of

Indexed as

Immune Checkpoint InhibitorsImmunotherapyNeoplasmsp21-Activated KinasesProgrammed Cell Death 1 ReceptorAnimalsCD8-Positive T-LymphocytesMiceImmune Checkpoint Inhibitorsp21-Activated KinasesPak4 protein, mouseProgrammed Cell Death 1 Receptor

Identifiers

PMID34368780
PMCPMC8340852
OpenAlexW2993691073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.